Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.

about

Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.

Item

http://www.wikidata.org/entity/Q41989387

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Effects of Maraviroc versus Ef ...... aive HIV-Infected Individuals.

@en

type

Item

label

Effects of Maraviroc versus Ef ...... aive HIV-Infected Individuals.

@en

prefLabel

Effects of Maraviroc versus Ef ...... aive HIV-Infected Individuals.

@en

P1476

Effects of Maraviroc versus Ef ...... aive HIV-Infected Individuals.

@en

P2093

Alexander Zlotnik

http://www.w3.org/2001/XMLSchema#string

Giorgia Caruana

http://www.w3.org/2001/XMLSchema#string

Santiago Moreno

http://www.w3.org/2001/XMLSchema#string

Sergio Serrano-Villar

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients

Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation

HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.

Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1

HIV infection, inflammation, immunosenescence, and aging.

Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.

Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly.

P31

scholarly article

P356

10.1128/AAC.01763-17

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

José Antonio Pérez-Molina

P577

2017-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28993335

http://www.w3.org/2001/XMLSchema#string

P932

5700350

http://www.w3.org/2001/XMLSchema#string